for testosterone therapy and the potential for adverse cardiovascular outcomes associated with testosterone replacement therapy. Related tickers: ( ABBV +0.7% ) ( LLY +0.9% ) ( AUXL -1.6% ) ( TEVA +1.8% ) Post your comment!
testosterone replacement therapy (TRT) and the potential for adverse cardiovascular outcomes associated with TRT. Briefing docs Related tickers: ( ABBV +0.1% ) ( LLY -0.1% ) ( AUXL -2.9% ) ( TEVA -1.4% ) Post your comment!
By Balanced Investing : Teva Pharmaceutical Industries Limited (NYSE: TEVA ) develops, manufactures, and markets generic, branded and OTC medicines. Teva Pharmaceutical is the world's largest generic company
By Chronic Bull : Mylan (NASDAQ: MYL ) was reiterated as a buy by the analysts at Argus although the company slightly lowered its 2014 earnings estimates. However, this pharmaceutical company has many other reasons to attract investors. The company has a growing portfolio of more than 1,300 generic
In a Phase 3b clinical study evaluating the incidence of injection-related adverse events, ( TEVA +0.1% ) finds that three-times-per-week injections of Copaxone 40 mg resulted in a 50% reduction in such events compared
(Corrects company name in headline to Teva Pharmaceutical from Teva Pharmaceuticals. Also, removes incorrect reference to Copaxone as an experimental MS drug)
on the market in Europe since 2007, and Teva 's Granix now competes with Neupogen in ..... in the United States. In the meantime, Teva is launching branded product Granix in ..... biosimilars to both products in Europe as well as Teva 's Granix (which competes with Neupogen
By Wall Street Breakfast : Economy Iraq's parliament approved a new government headed by Haider al-Abadi as prime minister last night, increasing the prospects for a more unified front to combat the growing power of Islamic State. Abadi's new cabinet includes members from Iraq's Shi'ite majority ...
this medication," says FTC Chairwoman Edith Ramirez. The commission also sued Teva Pharmaceutical Industries (NYSE: TEVA ) over allegations that AbbVie paid Teva to withdraw legal claims which could have led to a generic version of AndroGel
WASHINGTON, Sept 8 (Reuters) - The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, from getting to market.